AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2404388
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of streptokinase
Trial: 6356901
Drug: Labetalol alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol alone (100 to 1,200 mg twice a day)
Trial: 6356901
Drug: Labetalol in
RxNorm normalized name: labetalol Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol in combination with a diuretic
Trial: 6356901
Drug: Labetalol (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (with or without diuretic)
Trial: 31783766
Drug: Pelvic intensity‐modulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic intensity‐modulated radiation therapy (IMRT) of 50 Gy/25Fx concurrently with capecitabine and oxaliplatin (Arm A)
Trial: 27039894
Drug: Light‐emitting diode‐mediated‐photobiomodulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light‐emitting diode‐mediated‐photobiomodulation therapy (LPT) applied with an energy density of 20 mW/cm2 for 21 successive days (20 minutes per day) over the movement of canine teeth.
Trial: 27039894
Drug: Light‐emitting diode‐mediated‐photobiomodulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light‐emitting diode‐mediated‐photobiomodulation therapy (LPT)
Trial: 24215032
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab (IVB) injections (1.25 mg/0.05 mL)
Trial: 22504600
Drug: Monthly oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly oral periodic presumptive treatment (PPT; 2 g metronidazole + 150 mg fluconazole)
Trial: 17470024
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine spray
Trial: 15533734
Drug: C12 peptide
RxNorm normalized name: C12:0
DrugBank: Lauric acid (DB03017)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C12 peptide with higher dose of alginic acid (1754 mg)
Trial: 11973116
Drug: Telephone interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telephone interventions (two telephone contacts in addition to treatment as usual)
Trial: 11973116
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (no telephone interventions)
Trial: 9717819
Drug: 1.5 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/m2 9‐AC p.o. on day 1
Trial: 9717819
Drug: 1.0 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/m2 9‐AC i.v. on day 8
Trial: 1971599
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tertatolol
Trial: 2573371
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tertatolol with 1 g aspirin
Trial: 3279
Drug: L-prolyl-Lleucyl-glycine amide
RxNorm normalized name: L-arginyl-L-isoleucyl-L-valyl-L-prolyl-L-alanine-amide
DrugBank: Dusquetide (DB11879)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-prolyl-Lleucyl-glycine amide (PLG)
Trial: 27986405
Drug: 1-h post-load
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-h post-load plasma glucose <155 mg/dl
Trial: 27986405
Drug: 1-h post-load
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-h post-load plasma glucose ≥155 mg/dl
Trial: 23670707
Drug: Canagliflozin 50
RxNorm normalized name: canagliflozin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin 50 mg/day
Trial: 31001673
Drug: Canagliflozin 300
RxNorm normalized name: canagliflozin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin 300 mg/day
Trial: 19545297
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream applied 2 times per week
Trial: 19545297
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream applied 3 times per week
Trial: 19545297
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream applied 5 times per week
Trial: 19545297
Drug: Imiquimod 5%
RxNorm normalized name: Imiquimod 5% Topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imiquimod 5% cream applied 7 times per week
Trial: 1475090
Drug: 0.5 ml
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml of 1% acetylcholine chloride
Trial: 6397852
Drug: Flunarizine 5
RxNorm normalized name: flunarizine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine 5 mg b.i.d. during double-blind, cross-over medication period
Trial: 6397852
Drug: Placebo during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during double-blind, cross-over medication period
Trial: 30725387
Drug: Non-selective antimuscarinic
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-selective antimuscarinic drugs (trospium chloride, tolterodine tartrate, fesoterodine fumarate, propiverine hydrochloride)
Trial: 30725387
Drug: Selective antimuscarinic
RxNorm normalized name: ANTIMUSCARINICS/ANTISPASMODICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective antimuscarinic drugs (darifenacin hydrobromide, solifenacin succinate, oxybutynin hydrochloride)
Trial: 29663714
Drug: Mirogabalin (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirogabalin (10-40 mg single dose; 10, 15 mg twice a day repeated doses)
Trial: 27333407
Drug: 6.6 g
RxNorm normalized name: FERROUS SULFATE 76.6 g in 454 g TOPICAL POWDER [Hemostat]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.6 g Fortetropin supplementation
Trial: 27333407
Drug: 19.8 g
RxNorm normalized name: DIMETHICONE 19.8 g in 100 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 19.8 g Fortetropin supplementation
Trial: 25697893
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (O3FAs) - 2 capsules daily containing 180mg EPA and 120mg DHA for 3 months
Trial: 25697893
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - 2 capsules of olive oil daily for 3 months
Trial: 20578379
Drug: Vessel pricking
RxNorm normalized name: acellular tissue engineered vessel Drug Implant [Symvess]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vessel pricking therapy
Trial: 6219455
Drug: Prednisone (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (oral administration)
Trial: 19002265
Drug: cisplatin-based second-line
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cisplatin-based second-line therapy
Trial: 16877897
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin reuptake inhibitors (SSRIs) - fluoxetine or paroxetine (20 mg/day)
Trial: 10827368
Drug: Lidocaine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.5 to 2.5 mg/kg)
Trial: 1629506
Drug: Inhaled albuterol
RxNorm normalized name: albuterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled albuterol (ALB) with inhaled beclomethasone dipropionate (BDP)
Trial: 1629506
Drug: Inhaled albuterol
RxNorm normalized name: albuterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled albuterol (ALB) with oral theophylline (THEO)
Trial: 1629506
Drug: Inhaled albuterol
RxNorm normalized name: albuterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled albuterol (ALB), inhaled BDP, and oral THEO
Trial: 6333247
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose mediastinal radiation
Trial: 6333247
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy and radiotherapy (without low dose mediastinal radiation)
Trial: 6333247
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (combination chemotherapy and radiotherapy)
Trial: 24327173
Drug: Single eye-drop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single eye-drop containing 0.0175, 0.175, or 0.7 μg rhNGF
Trial: 24327173
Drug: Single ascending
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending dose of rhNGF eye drops three times a day for 1 day (total daily dose 2.1, 6.3, or 18.9 μg)
Trial: 24327173
Drug: Multiple ascending
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending dose of rhNGF eye drops three times a day for 5 days (total dose 10.5, 31.5, or 94.5 μg)
Trial: 22364387
Drug: 12 week
RxNorm normalized name: risedronate sodium 35 MG Oral Tablet, 12 Week Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 week exercise program including aerobic and strengthening exercises, conducted between 20 and 36 weeks of pregnancy, with one weekly group session led by physiotherapists and home exercises encouraged twice a week
Trial: 15753847
Drug: Higher C2
RxNorm normalized name: Gentamicin C2
DrugBank: Gentamicin C2 (DB17884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher C2 target range (1,000-1,200 ng/mL for months 4-6 and 800-1,000 ng/mL for months 7-12)
Trial: 15753847
Drug: Lower C2
RxNorm normalized name: Calendula Flower
DrugBank: Calendula officinalis flower (DB14263)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower C2 target range (800-1,000 ng/mL for months 4-6 and 600-800 ng/mL for months 7-12)
Trial: 10559813
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of normal saline (NS)
Trial: 10559813
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of lactated Ringer's solution (LR)
Trial: 10559813
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of lactated Ringer's solution with 5% dextrose (D5LR)
Trial: 2361193
Drug: Pilocarpine gel
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pilocarpine gel
Trial: 3377382
Drug: Pilocarpine 4%
RxNorm normalized name: PILOCARPINE 4% SOLN,OPH
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pilocarpine 4% solution
Trial: 22110164
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.5% solution
Trial: 22882084
Drug: Start For
RxNorm normalized name: Star Anise Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Start For Life treatment (30 minutes daily of structured physical activity with behavioral and self-regulatory skills training)
Trial: 24114718
Drug: Start For
RxNorm normalized name: Star Anise Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Start For Life treatment
Trial: 21598057
Drug: Intensive glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glucose control (target 4.4‐6.1 mmoL·L(‐1) or 80‐110 mg·dL(‐1))
Trial: 21598057
Drug: Conventional glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glucose control (target 10‐11.1 mmoL·L(‐1) or 180‐200 mg·dL(‐1))
Trial: 16685055
Drug: Soymilk (71.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soymilk (71.6 mg isoflavones from 706 mL soymilk/d)
Trial: 16685055
Drug: Supplement (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement (70 mg isoflavones in a supplement plus 706 mL cow milk/d)
Trial: 16685055
Drug: Control (706
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (706 mL cow milk/d plus a placebo supplement)
Trial: 11780680
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (CoQ) 60 mg orally twice daily for 12 weeks
Trial: 23453459
Drug: Anakinra (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (100 mg/day for 14 days)
Trial: 18371034
Drug: Surfactant replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant replacement therapy (bovine lung surfactant extract) with standard treatment for RDS
Trial: 18371034
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care for RDS without surfactant therapy
Trial: 14519175
Drug: Bupropion (sustained-release)
RxNorm normalized name: bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion (sustained-release)
Trial: 10949981
Drug: Gemifloxacin (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemifloxacin (320 mg once-daily for 5 days)
Trial: 10949981
Drug: Amoxicillin/clavulanate (500/125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate (500/125 mg three-times daily for 7 days)
Trial: 9171971
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (rhGH) and resistance exercise
Trial: 3769187
Drug: Intravenous dipyridamole
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous dipyridamole (0.24 mg/kg/hr)
Trial: 29071914
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group receiving estradiol valerate (1 mg/day for 3 weeks, followed by a week of rest, then 1 mg/day and medroxyprogesterone 17-acetate (8 mg/day) for 10 days).
Trial: 18602688
Drug: Vitespen (HSPPC-96);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitespen (HSPPC-96); administered intradermally once a week for 4 weeks, then every 2 weeks until vaccine depletion
Trial: 18602688
Drug: Vitespen (HSPPC-96);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitespen (HSPPC-96); administered intradermally
Trial: 16007029
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (n=18)
Trial: 12192554
Drug: Radioiodine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine therapy with doses of 150 Gy
Trial: 12192554
Drug: Radioiodine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine therapy with doses of 300 Gy
Trial: 12192554
Drug: Radioiodine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radioiodine therapy with target dose of 256 Gy
Trial: 2967184
Drug: Bisoprolol 5
RxNorm normalized name: bisoprolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol 5 mg once daily
Trial: 31009768
Drug: 1 mm
RxNorm normalized name: PhaSeal Protector, 21 mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mm allograft bone particles (ABP) augmentation in groups A1 and A2
Trial: 31009768
Drug: Full (100%)
RxNorm normalized name: Full Marks
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full (100%) trajectory augmentation with 1 mm ABP in groups B1 and B2
Trial: 20163941
Drug: Comprehensive lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive lifestyle intervention (L)
Trial: 15585768
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract supplement
Trial: 11723089
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (diuretics and/or beta-blockers)
Trial: 8995946
Drug: Citrucel, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrucel, 1 tablespoon twice daily
Trial: 8995946
Drug: Pectin, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pectin, 1 tablespoon twice daily
Trial: 8515979
Drug: Controlled-release ibuprofen
RxNorm normalized name: ibuprofen Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release ibuprofen 600 mg
Trial: 8515979
Drug: Regular ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Regular ibuprofen 200 mg (3 doses)
Trial: 8515979
Drug: Codeine 30
RxNorm normalized name: codeine 30 MG
DrugBank: Codeine (DB00318)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Codeine 30 mg (3 doses)
Trial: 30809700
Drug: BetterStim sacral
RxNorm normalized name: Boswellia sacra whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BetterStim sacral neuromodulation system (treatment group)
Trial: 19921102
Drug: Glycoprotein IIb-IIIa
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoprotein IIb-IIIa inhibitors with Drug-Eluting Stents (DES)
Trial: 19921102
Drug: Glycoprotein IIb-IIIa
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoprotein IIb-IIIa inhibitors with Bare Metal Stents (BMS)
Trial: 18570578
Drug: Cefoperazone-sulbactam (2-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoperazone-sulbactam (2-8 g/day)
Trial: 18570578
Drug: Ceftazidime-amikacin-metronidazole (2-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime-amikacin-metronidazole (2-6 g/day, 15 mg/kg/day, 500 mg three times daily)
Trial: 15845094
Drug: Sodium lactate
RxNorm normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium lactate infusion (0.5 M, 5 mL/kg body weight)
Trial: 27415
Drug: 0.9% NaCl
RxNorm normalized name: Trace Metals Additive in 0.9% NaCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl infusion
Trial: 10064170
Drug: Oral isoprinosine
RxNorm normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral isoprinosine
Trial: 10064170
Drug: Oral isoprinosine
RxNorm normalized name: isoprenaline
DrugBank: Isoprenaline (DB01064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral isoprinosine plus intraventricular alpha-interferon
Trial: 8756801
Drug: Salmeterol (Sm)
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Salmeterol (Sm) 50 micrograms twice daily
Trial: 8756801
Drug: Salbutamol (Sb)
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol (Sb) 200 micrograms four times daily
Trial: 1901200
Drug: Rifater (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifater (combined formulation)
Trial: 28991149
Drug: Fluid Outpatient
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid Outpatient Rehabilitation Treatment (FORT)
Trial: 28991149
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment planning
Trial: 27256458
Drug: Preheated skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preheated skin disinfectant solution (36 °C)
Trial: 27256458
Drug: Room-temperature skin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room-temperature skin disinfectant solution (20 °C)
Trial: 17239678
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment with intracoronary injection of BM-SCs
Trial: 17239678
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment with combined application of BM-SCs
Trial: 17239678
Drug: Late treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late treatment with intracoronary delivery of BM-SCs
Trial: 17239678
Drug: Late treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late treatment with combined administration of BM-SCs
Trial: 17239678
Drug: Standardized treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized treatment of AMI (control for all groups)
Trial: 12032655
Drug: Combination beta-carotene
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination beta-carotene and vitamin E
Trial: 10580202
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses at 2, 4, and 6 months
Trial: 10580202
Drug: Third dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third dose in the Swedish arm
Trial: 10580202
Drug: Fourth dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fourth dose in the US arm
Trial: 10580202
Drug: Higher diphtheria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher diphtheria toxoid dose (25 Lf) in the Swedish arm
Trial: 10580202
Drug: Higher tetanus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher tetanus toxoid dose (7 Lf) in the Swedish arm
Trial: 10580202
Drug: Increasing the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing the number of doses, prolonging intervals between doses, and increasing antigen amount
Trial: 6357677
Drug: Fenoterol (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol (0.1 mg)
Trial: 29117618
Drug: Flaxseed oil
RxNorm normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed oil omega-3 fatty acids (1,000 mg, twice a day for 12 weeks)